



Investor Presentation

April 2020

Disclaimer



NOT AN OFFER OF SECURITIES

This document has been independently prepared by Little Green Pharma Ltd ACN 615 586 215 (LGP) and is provided for informational purposes only.

This document does not constitute or contain an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in LGP. This document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in any jurisdiction (in particular, the United States), or a securities recommendation. This document is not a prospectus, product disclosure statement or other offering document under Australian law or any other law, and will not be lodged with the Australian Securities and Investments Commission.

Summary information

This document contains a summary of information about LGP and its activities that is current as at the date of this document. The information in this document is general in nature and does not purport to be complete or to contain all the information which a prospective investor may require in evaluating a possible investment in LGP or that would be required in a prospectus or a product disclosure statement prepared in accordance with the Corporations Act 2001 (Cth) (Corporations Act).

No liability

The information contained in this document has been prepared in good faith by LGP, however no guarantee representation or warranty expressed or implied is or will be made by any person (including LGP and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this document.

To the maximum extent permitted by law, LGP and its affiliates and their directors, officers, employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice. No responsibility or liability is assumed by LGP or any of its affiliates for updating any information in this document or to inform any recipient of any new or more accurate information or any errors or mis-descriptions of which LGP and any of its affiliates or advisers may become aware.

Forward looking statement

Certain information in this document refers to the intentions of LGP, but these are not intended to be forecasts, forward looking statements or statements about the future matters for the purposes of the Corporations Act or any other applicable law. The occurrence of the events in the future are subject to risk, uncertainties and other actions that may cause LGP's actual results, performance or achievements to differ from those referred to in this document. Accordingly LGP and its affiliates and their directors, officers, employees and agents do not give any assurance or guarantee that the occurrence of these events referred to in the document will actually occur as contemplated.

Statements contained in this document, including but not limited to those regarding the possible or assumed future costs, performance, dividends, returns, revenue, exchange rates, potential growth of LGP, industry growth or other projections and any estimated company earnings are or may be forward looking statements. Forward-looking statements can generally be identified by the use of words such as 'project', 'foresee', 'plan', 'expect', 'aim', 'intend', 'anticipate', 'believe', 'estimate', 'may', 'should', 'will' or similar expressions. These statements relate to future events and expectations and as such involve known and unknown risks and significant uncertainties, many of which are outside the control of LGP. Actual results, performance, actions and developments of LGP may differ materially from those expressed or implied by the forward-looking statements in this document.

Such forward-looking statements speak only as of the date of this document. There can be no assurance that actual outcomes will not differ materially from these statements. To the maximum extent permitted by law, LGP and any of its affiliates and their directors, officers, employees, agents, associates and advisers:

- disclaim any obligations or undertaking to release any updates or revisions to the information to reflect any change in expectations or assumptions;
- do not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information in this document, or likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement; and
- disclaim all responsibility and liability for these forward-looking statements (including, without limitation, liability for negligence).

Not financial product advice

This document does not constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists purely of factual information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product.

An investment in LGP is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document.

Information in this document is confidential

This document and the information contained within it are strictly confidential and are intended for the exclusive benefit of the persons to whom it is given. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of LGP. By receiving this document, you agree to keep the information confidential, not to disclose any of the information contained in this document to any other person and not to copy, use, publish, record or reproduce the information in this document without the prior written consent of LGP, which may be withheld in its absolute discretion.

Acceptance

By attending an investor presentation or briefing, or accepting, accessing or reviewing this document you acknowledge and agree to the "Disclaimer" as detailed above.

Why LGP

Company Highlights



Generating revenue - month on month increase



First company to export Australian medicinal cannabis products



Manufacturing partner - EU-GMP recognised



Expanded cultivation facility enabling production capacity up to 110,000 bottles p/a



Construction of own manufacturing facility underway



Developing unique drug delivery system and product offering



Lean business model

Company Overview

Little Green Pharma is a leading vertically integrated medicinal cannabis business¹ with existing sales and a clear pathway to increasing margins & driving significant revenue growth in domestic & European markets



Vertically integrated producer of medicinal cannabis

Controls entire medicinal cannabis supply chain - cultivation, production, and manufacturing capabilities¹



Expansion of cultivation facility completed in Q1 2020

Increases cultivation capacity enabling production increase from 15,000 to 110,000 bottles of medicinal cannabis oil p.a.



Strong in-market brand

Currently selling range of four THC and CBD products with future products in the proposed R&D pipeline



Successful track record of commercialization

3,175+ patients using LGP products in AU²
10,450+ bottles of medicinal cannabis oil sold since Aug 2018²
2,400 unit purchase order from CC Pharma



Clear path to distribution in Australia and Europe

Multi-year sales agreements with leading distributors in the UK and Germany for the sale, export, import and distribution of LGP's medicinal cannabis products




Strong focus on patient access and product innovation

Driving patient access through education and outreach programs. Multiple clinical investigations & research projects underway to develop innovative new delivery systems

1. LGP has an exclusive agreement with a TGA-GMP certified medicinal cannabis manufacturer who can only terminate the agreement after 22 November 2023 and with 12 months' notice.
2. As at 31 March 2020

Our Business Model Captures Value

Integrated model captures the medicinal cannabis value chain




Growth Strategy



1. LGP has an exclusive agreement with a TGA-GMP certified medicinal cannabis manufacturer who can only terminate the agreement after 22 November 2023 and with 12 months' notice.

We have a track record of growing patient access

Strong growth in sales and patients using LGP products in Australia



1. CMGR = Compound Monthly Growth Rate, since January 2019

■ Unique Patients Using LGP Products (RHS)
 ■ LGP Cumulative Bottle Sold (LHS)

Our financial & operational metrics on a positive growth trend

Significant operational momentum



Revenue (H1FY20)
Up **188%** to **\$716,000**
for 6 months vs. 12 months to FY19




Gross Margin (H1FY20)
54%¹, up from **41%**
vs. FY19




Biological Assets (H1FY20)
Up **30%** to **\$667,570**
vs. end FY19



Patients (to 31 Mar 2020)
3,175+
vs. 2,900+ to 29 Feb 2020



Prescribers (to 31 Mar 2020)
240+
vs. 210 to 29 Feb 2020



Bottles Sold (to 31 Mar 2020)
10,450+
vs. 8,900+ to 29 Feb 2020

1. Gross Margin is 70% including biological asset adjustment

We have made solid progress since ASX listing

LGP has made considerable commercial progress since October 2019



Executed EU Sales Agreements

3-year sales agreement signed with DEMECAN (Germany) for up to 1,000kg of dried flower or 48,000 units of oil product, or a combination thereof p.a.¹

5-year sales agreement signed with Astral Health (UK) to supply suite of medicinal cannabis products²



Licence & Facility

Granted expansion to Medicinal Cannabis Cultivation and Production Licence and **new Manufacturing Licence**

Cultivation facility commissioned and once permitted will be able to produce sufficient flower to manufacture 110,000 bottles p.a.



Partnerships

Supply agreement for research with the Australian Centre for Cannabinoid Clinical and Research Excellence through the University of Newcastle

Exclusive partnership with Curtin University for use of ARISE technology for product development



Product

New product
LGP Classic CBD 50 released in February 2020



1. See ASX announcement “German Purchase Agreement with Demecan” – 27 February 2020
2. See ASX announcement “Binding Purchase Agreement with UK-based Astral Health” – 19 February 2020

News Flow

Significant news flow as LGP executes growth strategy



Completion of cultivation facility expansion



First product delivered to Astral Health in the UK



Further expansion of product line with new *LGP Classic CBD 50* product



Final permit granted and first crop planting at expanded facility



First large commercial quantity delivered to Astral Health in the UK



Update on progress of own manufacturing facility



Fulfilment of CC Pharma order



Delivery of first products to DEMECAN in Germany



Further research & results from ongoing clinical investigations

Corporate Overview

Snapshot

- Listed on the ASX on 20 February 2020
- Raised \$10 million at IPO
- No debt
- 11,659,258 shares escrowed 6-12 months from listing
- 54,034,703 shares escrowed 24 months from listing

Capital Structure

Current Share Price ²	\$0.28
Shares Outstanding	133,501,069
Options and Performance Rights on Issue	21,923,536
Market Capitalisation (undiluted) ²	~\$37.4 million
Cash Reserves (31 March 2020)	~\$6.0 million
Enterprise Value	~\$31.4 million

Shareholders¹

Shareholders ¹	Shareholding	Ownership
Elixer Ltd.	30.8m	23.1%
Fleta Solomon	19.6m	14.7%
Angus Caithness	5.5m	4.1%
GSCO - ECA Resource Geologic Partners	5.4m	4.0%
TIGA Trading Pty Ltd, Asset Management Arm	3.4m	2.5%
Jenny Mckay	3.3m	2.5%
Mutual Trust Pty Ltd, Asset Management Arm	2.8m	2.1%
Corpserv Pty. Ltd.	2.3m	1.7%
Mary Davis	1.4m	1.0%
Heavenly Star Pty Ltd	1.3m	0.9%
Ceres Capital Pty Ltd	1.2m	0.9%
Pfl Green Growth Pty Ltd	1.1m	0.8%
Geneva Benkovic	1.1m	0.8%
Robert Benkovic	1.0m	0.8%
Anthony McIntosh	1.0m	0.8%
Neale Fong	1.0m	0.7%
Louise Pilkington	0.6m	0.5%
Sean Reid	0.6m	0.5%
Michael Lynch-Bell	0.6m	0.4%
Board ownership	26.7m	20.0%
Total shares outstanding	133.5m	

1. Source: IRESS - As at 31 March 2020

2. As at 29 April 2020

An abstract graphic of a green leaf, rendered with layered, semi-transparent shapes that create a sense of depth and movement. The leaf is positioned on the left side of the page, with its tip pointing towards the bottom left corner. The background is a solid, light green color.

little
green
pharma

little
green
pharma